A COMPARATIVE ANALYSIS OF EFFICACY OF INTERFERON BETA 1-B AND NATALIZUMAB TREATMENT IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS

Cover Page

Cite item

Abstract

Background: Disease modifying drugs for multiple sclerosis have similar indications for use and at the same time, their specifics of the effect on the pathophysiological process. This complicates the choice of an optimal therapy for a  given patient. Aim: To assess efficacy of treatment for multiple sclerosis with interferon beta-1b (IFN-β-1b) and natalizumab. Materials and methods: We performed an open label prospective study in 110  patients with multiple sclerosis who were followed up in the Moscow Regional Center of multiple sclerosis from 2012 to 2015. From those, 99  patients with relapsing-remitting multiple sclerosis (disease modifying drugs naïve) were treated with IFN-β-1b, 11 were non-responders to interferon (1 and more attacks for the previous year of therapy with IFN-β-1b) or had progressive course of multiple sclerosis (more than 2  attacks and an increase in the Expanded Disability Status Scale (EDSS) score by 1 and more within 1 year) and were treated with natalizumab. Analysis of treatment efficacy was performed with consideration of their past history, results of a  3-year neuromonitoring with Kurtzke EDSS and Functional System Scale, neuroophthalmologic testing with Farnsworth dichotomous test, and changes in optical coherent tomography parameters. Results: During 3  years of treatment with IFN-β-1b, the mean number of attacks decreased by over 70% (from 1.28±0.7 in the year before treatment to 0.35±0.09 in the 3rd year of treatment; p<0.05), whereas the degree of disability assessed by EDSS increased nonsignificantly by 0.44 (p>0.05). During the follow-up in the natalizumab group, the number of attacks decreased from 2.3±0.04 to 0.13±0.01 (p<0.05), and the degree of disability by EDSS decreased by 0.8 (p>0.05). There was a significant difference between changes in the thickness of peripapillar nervous fibers during 2  years of the follow up, this parameter decreasing by 2.5 mcm in patients treated with IFN-β-1b and by 0.1  mcm in those treated with natalizumab (p<0.01). Conclusion: Although the patients from natalizumab group had initial more severe course of multiple sclerosis, both agents were highly effective, with the most prominent clinical effect observed for natalizumab. The results obtained may serve as a  basis for recommendation of the 2nd line disease modifying drugs for patients with aggressive course of the multiple sclerosis and failure of the 1st line disease modifying drugs. Also, we were able to demonstrate the efficacy of neuroophthalmological monitoring in the assessment of disease modifying drugs efficacy. The strict safety policy is essential while using natalizumab.

About the authors

T. I. Yakushina

Moscow Regional Research and Clinical Institute (MONIKI)

Email: fake@neicon.ru

MD, PhD, Senior Research Fellow, Department of Neurology

61/2 Shchepkina ul., Moscow, 129110

Russian Federation

S. V. Kotov

Moscow Regional Research and Clinical Institute (MONIKI)

Author for correspondence.
Email: kotovsv@yandex.ru

MD, PhD, Professor; Head of Department of Neurology; Head of Chair of Neurology, Postgraduate Training Faculty

61/2–10 Shchepkina ul., Moscow, 129110

Tel.: +7 (495) 631 73 62

Russian Federation

M. A. Yakushin

Moscow Regional Research and Clinical Institute (MONIKI)

Email: fake@neicon.ru

MD, PhD, Professor, Chair of Neurology, Postgraduate Training Faculty

61/2 Shchepkina ul., Moscow, 129110

Russian Federation

Yu. A. Belova

Moscow Regional Research and Clinical Institute (MONIKI)

Email: fake@neicon.ru

MD, PhD, Research Fellow, Department of Neurology

61/2 Shchepkina ul., Moscow, 129110

Russian Federation

N. V. Kuchina

Moscow Regional Research and Clinical Institute (MONIKI)

Email: fake@neicon.ru

Postgraduate Student, Chair of Neurology, Postgraduate Training Faculty

61/2 Shchepkina ul., Moscow, 129110

Russian Federation

O. M. Andryukhina

Moscow Regional Research and Clinical Institute (MONIKI)

Email: fake@neicon.ru

MD, Research Fellow, Department of Ophthalmology

61/2 Shchepkina ul., Moscow, 129110

Russian Federation

References

  1. Río J, Tintoré M, Nos C, Téllez N, Galán I, Montalban X. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre. J Neurol. 2005;252(7):795–800. doi: 10.1007/s00415- 005-0748-5.
  2. Котов СВ, Якушина ТИ, Лиждвой ВЮ. Длительное сравнительное исследование эффективности препаратов, изменяющих течение рассеянного склероза. Альманах клинической медицины. 2011;25:37–40.
  3. Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology. 1993;43(4):662–7.
  4. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993;43(4): 655–61.
  5. Попова ЕВ, Бойко АН, Васильев АВ, Давыдовская МВ, Завалишин ИА, Котов СВ, Кротенкова МВ, Хачанова НВ, Шаранова СН, Щур СГ, Якушина ТИ. Результаты сравнительного клинического исследования российского биоаналога β интерферона 1b (инфибета). Журнал неврологии и психиатрии им. С.С. Корсакова. 2012;112(5):56–61.
  6. Попова ЕВ, Бойко АН, Васильев АВ, Давыдовская МВ, Завалишин ИА, Котов СВ, Кротенкова МВ, Хачанова НВ, Шаранова СН, Щур СГ, Якушина ТИ. Результаты клинического исследования препарата Инфибета (II–III фаза). Рекомендации по переводу пациентов с рассеянным склерозом на биоаналоги. Consilium medicum. 2012;14(2): 120–5.
  7. Якушина ТИ, Елисеев ЮВ, Котов СВ. Редкий случай неэффективности терапии натализумабом (Тизабри) у пациентки с рассеянным склерозом и нейтрализующими антителами к препарату. Журнал неврологии и психиатрии им. С.С. Корсакова. 2013;113(2–2):83–6.
  8. Сидоренко ТВ, Кольяк ЕВ, Бойко АН. Натализумаб: новый препарат для лечения рассеянного склероза. Журнал неврологии и психиатрии им. С.С. Корсакова. 2009;109(7–2):122–8.
  9. Rommer PS, Stüve O, Goertsches R, Mix E, Zettl UK. Monoclonal antibodies in the therapy of multiple sclerosis: an overview. J Neurol. 2008;255 Suppl 6:28–35. doi: 10.1007/s00415- 008-6006-x.
  10. Stüve O, Gold R, Chan A, Mix E, Zettl U, Kieseier BC. Alpha4-Integrin antagonism with natalizumab: effects and adverse effects. J Neurol. 2008;255 Suppl 6:58–65. doi: 10.1007/s00415- 008-6011-0.
  11. Hutchinson M, Kappos L, Calabresi PA, Confavreux C, Giovannoni G, Galetta SL, Havrdova E, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol. 2009;256(3):405–15. doi: 10.1007/ s00415-009-0093-1.
  12. Rudick RA, Panzara MA. Natalizumab for the treatment of relapsing multiple sclerosis. Biologics. 2008;2(2):189–99.
  13. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, Willmer-Hulme AJ, Dalton CM, Miszkiel KA, O'Connor PW; International Natalizumab Multiple Sclerosis Trial Group. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003;348(1):15–23.
  14. O'Connor PW, Goodman A, Willmer-Hulme AJ, Libonati MA, Metz L, Murray RS, Sheremata WA, Vollmer TL, Stone LA; Natalizumab Multiple Sclerosis Trial Group. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology. 2004;62(11):2038–43.
  15. Кучина НВ, Якушина ТИ, Котов СВ, Лапитан ДГ, Андрюхина ОМ, Рябцева АА. Исследование цветового зрения для диагностики и динамического наблюдения при рассеянном склерозе. Альманах клинической медицины. 2015;36:47–52. doi: 10.18786/2072- 0505-2015-36-47-52.
  16. Андрюхина ОМ, Рябцева АА, Котов СВ, Якушина ТИ, Кучина НВ. Мониторинг офтальмологических индикаторов у больных рассеянным склерозом. Альманах клинической медицины. 2015;36:53–8. doi: 10.18786/2072- 0505-2015-36-53-58.

Copyright (c) 2016 Yakushina T.I., Kotov S.V., Yakushin M.A., Belova Y.A., Kuchina N.V., Andryukhina O.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies